Subscribe
Switching MS patients to subcutaneous ocrelizumab cut chair time 82.8% and delivered $514,544 in 3-year value, a UVA analysis finds.
Specialty Pharmacies See Patients With MS Often but Lack the Right Tool to Measure Decline
Myasthenia Gravis Linked to Greater Longevity Than Multiple Sclerosis
GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis
Rituximab Matches Ocrelizumab in Head-to-Head MS Trial
